General morphological and biological features of neoplasms: Integration of molecular findings

Histopathology

Volumn 53, Issue 1, 2008, Pages 1-19

  Diaz Cano, S J ^a  

^a KING S COLLEGE HOSPITAL   (United Kingdom)

Author keywords

Cell kinetics; Differentiation; Genetic instability; Molecular pathology; Neoplasia; Pathogenesis; Progression; Tumour heterogeneity; Tumour microenvironment

Indexed keywords

BRCA1 PROTEIN; BRCA2 PROTEIN; CELL CYCLE PROTEIN; CYCLIN D1; CYCLIN DEPENDENT KINASE 1; CYCLIN DEPENDENT KINASE 2; CYCLIN DEPENDENT KINASE 4; CYTOCHROME C; DNA; GROWTH FACTOR; HISTONE; MITOCHONDRIAL PROTEIN; ONCOPROTEIN; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN; PROTEIN P53; TELOMERASE; TUMOR NECROSIS FACTOR RECEPTOR 1;

APOPTOSIS; CANCER CELL; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL DIFFERENTIATION; CELL DIVISION; CELL SURVIVAL; CHROMATIN CONDENSATION; CHROMOSOMAL INSTABILITY; DNA DAMAGE; DNA REPAIR; DNA SYNTHESIS; EPIGENETICS; GENETIC HETEROGENEITY; GENETIC TRANSCRIPTION; HISTOPATHOLOGY; HUMAN; MALIGNANT TRANSFORMATION; METASTASIS; MICROSATELLITE INSTABILITY; MITOCHONDRION; MOLECULAR GENETICS; MORPHOLOGY; NEOPLASM; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS; PURINE SYNTHESIS; REVIEW; RIBOSOME; TRANSCRIPTION REGULATION; TUMOR VASCULARIZATION;

DISEASE PROGRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, NEOPLASM; GENES, TUMOR SUPPRESSOR; HUMANS; MOLECULAR BIOLOGY; NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 45549090039     PISSN: 03090167     EISSN: 13652559     Source Type: Journal    
DOI: 10.1111/j.1365-2559.2007.02937.x     Document Type: Review

References (100)

1. Hanahan D, Weinberg RA. The hallmarks of cancer. Cell 2000 100 57 70.
2. Blanes A, Diaz-Cano SJ. DNA and kinetic heterogeneity during the clonal evolution of adrenocortical proliferative lesions. Hum. Pathol. 2006 37 1295 1303.
3. Blanes A, Rubio J, Martinez A, Wolfe HJ, Diaz-Cano SJ. Kinetic profiles by topographic compartments in muscle-invasive transitional cell carcinomas of the bladder: role of TP53 and NF1 genes. Am. J. Clin. Pathol. 2002 118 93 100.
4. Diaz-Cano SJ, Blanes A, Wolfe HJ. PCR techniques for clonality assays. Diagn. Mol. Pathol. 2001 10 24 33.
5. Diaz-Cano SJ, de Miguel M, Blanes A, Tashjian R, Galera H, Wolfe HJ. Clonality as expression of distinctive cell kinetics patterns in nodular hyperplasias and adenomas of the adrenal cortex. Am. J. Pathol. 2000 156 311 319.
6. Pozo-Garcia L, Diaz-Cano SJ. Clonal origin and expansions in neoplasms: biologic and technical aspects must be considered together. Am. J. Pathol. 2003 162 353 354 author reply 354 355.
7. Kinzler KW, Vogelstein B. Lessons from hereditary colorectal cancer. Cell 1996 87 159 170.
8. Diaz-Cano SJ, de Miguel M, Blanes A, Tashjian R, Wolfe HJ. Germline RET 634 mutation positive MEN 2A-related C-cell hyperplasias have genetic features consistent with intraepithelial neoplasia. J. Clin. Endocrinol. Metab. 2001 86 3948 3957.
9. Mears L, Diaz-Cano SJ. Difference between familial and sporadic medullary thyroid carcinomas. Am. J. Surg. Pathol. 2003 27 266 267.
10. Alizadeh AA, Eisen MB, Davis RE et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000 403 503 511.
11. Bittner M, Meltzer P, Chen Y et al. Molecular classification of cutaneous malignant melanoma by gene expression profiling. Nature 2000 406 536 540.
12. Dhanasekaran SM, Barrette TR, Ghosh D et al. Delineation of prognostic biomarkers in prostate cancer. Nature 2001 412 822 826.
13. Ahr A, Holtrich U, Solbach C et al. Molecular classification of breast cancer patients by gene expression profiling. J. Pathol. 2001 195 312 320.
14. Alizadeh AA, Ross DT, Perou CM, van de Rijn M. Towards a novel classification of human malignancies based on gene expression patterns. J. Pathol. 2001 195 41 52.
15. Carvajal-Carmona LG, Howarth KM, Lockett M et al. Molecular classification and genetic pathways in hyperplastic polyposis syndrome. J. Pathol. 2007 212 378 385.
16. Harris AL. Hypoxia - a key regulatory factor in tumour growth. Nat. Rev. Cancer 2002 2 38 47.
17. Li F, Tiede B, Massague J, Kang Y. Beyond tumorigenesis: cancer stem cells in metastasis. Cell Res. 2007 17 3 14.
18. Keith B, Simon MC. Hypoxia-inducible factors, stem cells, and cancer. Cell 2007 129 465 472.
19. Semenza GL. HIF-1, O(2), and the 3 PHDs: how animal cells signal hypoxia to the nucleus. Cell 2001 107 1 3.
20. Gupta GP, Massague J. Cancer metastasis: building a framework. Cell 2006 127 679 695.
21. Kang Y, Massague J. Epithelial-mesenchymal transitions: twist in development and metastasis. Cell 2004 118 277 279.
22. Brabletz T, Jung A, Spaderna S, Hlubek F, Kirchner T. Opinion: migrating cancer stem cells - an integrated concept of malignant tumour progression. Nat. Rev. Cancer 2005 5 744 749.
23. Nguyen DX, Massague J. Genetic determinants of cancer metastasis. Nat. Rev. Genet. 2007 8 341 352.
24. Diaz-Cano SJ, Blanes A, Rubio J, Matilla A, Wolfe HJ. Molecular evolution and intratumor heterogeneity by topographic compartments in muscle-invasive transitional cell carcinoma of the urinary bladder. Lab. Invest. 2000 80 279 289.
25. Blanes A, Sanchez-Carrillo JJ, Diaz-Cano SJ. Topographic molecular profile of pheochromocytomas: role of somatic down-regulation of mismatch repair. J. Clin. Endocrinol. Metab. 2006 91 1150 1158.
26. Arif S, Patel J, Blanes A, Diaz-Cano SJ. Cytoarchitectural and kinetic features in the histological evaluation of follicular thyroid neoplasms. Histopathology 2007 50 750 763.
27. Diaz-Cano SJ. Kinetic topographical heterogeneity in follicular thyroid neoplasms and growth patterns. Histopathology 2007 51 416 418.
28. Pozo L, Sanchez-Carrillo J, Martinez A, Blanes A, Diaz-Cano S. Differential kinetic features by tumour topography in cutaneous small-cell neuroendocrine (Merkel cell) carcinomas. J. Eur. Acad. Dermatol. Venereol. 2007 21 1220 1228.
29. Rubio J, Blanes A, Sanchez-Carrillo JJ, Diaz-Cano SJ. Microsatellite abnormalities and somatic down-regulation of mismatch repair characterize nodular-trabecular muscle-invasive urothelial carcinoma of the bladder. Histopathology 2007 51 458 467.
30. Kinzler KW, Vogelstein B. Landscaping the cancer terrain. Science 1998 280 1036 1037.
31. Kaldis P. Another piece of the p27Kip1 puzzle. Cell 2007 128 241 244.
32. Kim WY, Sharpless NE. The regulation of INK4/ARF in cancer and aging. Cell 2006 127 265 275.
33. Campisi J. Senescent cells, tumor suppression, and organismal aging: good citizens, bad neighbors. Cell 2005 120 513 522.
34. Sherr CJ. Cancer cell cycles. Science 1996 274 1672 1677.
35. Derynck R, Zhang Y, Feng XH. Smads: transcriptional activators of TGF-beta responses. Cell 1998 95 737 740.
36. Shi Y, Massague J. Mechanisms of TGF-beta signaling from cell membrane to the nucleus. Cell 2003 113 685 700.
37. Bar-Sagi D, Hall A. Ras and Rho GTPases: a family reunion. Cell 2000 103 227 238.
38. Yaswen P, Campisi J. Oncogene-induced senescence pathways weave an intricate tapestry. Cell 2007 128 233 234.
39. Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 1997 88 323 331.
40. Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, Alt FW. DNA repair, genome stability, and aging. Cell 2005 120 497 512.
41. Sherr CJ. Principles of tumor suppression. Cell 2004 116 235 246.
42. Baker SJ. PTEN enters the nuclear age. Cell 2007 128 25 28.
43. Di Cristofano A, Pandolfi PP. The multiple roles of PTEN in tumor suppression. Cell 2000 100 387 390.
44. Rossi DJ, Weissman IL. Pten, tumorigenesis, and stem cell self-renewal. Cell 2006 125 229 231.
45. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell 2007 129 1261 1274.
46. Locksley RM, Killeen N, Lenardo MJ. The TNF and TNF receptor superfamilies: integrating mammalian biology. Cell 2001 104 487 501.
47. Varfolomeev EE, Ashkenazi A. Tumor necrosis factor: an apoptosis JuNKie? Cell 2004 116 491 497.
48. Harris MH, Thompson CB. The role of the Bcl-2 family in the regulation of outer mitochondrial membrane permeability. Cell Death Differ. 2000 7 1182 1191.
49. Joza N, Susin SA, Daugas E et al. Essential role of the mitochondrial apoptosis-inducing factor in programmed cell death. Nature 2001 410 549 554.
50. Shi Y. A structural view of mitochondria-mediated apoptosis. Nat. Struct. Biol. 2001 8 394 401.
51. Srinivasula SM, Hegde R, Saleh A et al. A conserved XIAP-interaction motif in caspase-9 and Smac/DIABLO regulates caspase activity and apoptosis. Nature 2001 410 112 116.
52. Brazil DP, Park J, Hemmings BA. PKB binding proteins. Getting in on the Akt. Cell 2002 111 293 303.
53. Zhang J, Xu M. Apoptotic DNA fragmentation and tissue homeostasis. Trends Cell Biol. 2002 12 84 89.
54. Enari M, Sakahira H, Yokoyama H, Okawa K, Iwamatsu A, Nagata S. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD. Nature 1998 391 43 50.
55. Sakahira H, Enari M, Nagata S. Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis. Nature 1998 391 96 99.
56. Durrieu F, Samejima K, Fortune JM, Kandels-Lewis S, Osheroff N, Earnshaw WC. DNA topoisomerase IIalpha interacts with CAD nuclease and is involved in chromatin condensation during apoptotic execution. Curr. Biol. 2000 10 923 926.
57. Li LY, Luo X, Wang X. Endonuclease G is an apoptotic DNase when released from mitochondria. Nature 2001 412 95 99.
58. Parrish J, Li L, Klotz K, Ledwich D, Wang X, Xue D. Mitochondrial endonuclease G is important for apoptosis in C. elegans. Nature 2001 412 90 94.
59. Chang S, DePinho RA. Telomerase extracurricular activities. Proc. Natl Acad Sci USA 2002 99 12520 12522.
60. Shay JW, Zou Y, Hiyama E, Wright WE. Telomerase and cancer. Hum. Mol. Genet. 2001 10 677 685.
61. Wang J, Hannon GJ, Beach DH. Risky immortalization by telomerase. Nature 2000 405 755 756.
62. Stewart SA, Hahn WC, O'Connor BF et al. Telomerase contributes to tumorigenesis by a telomere length-independent mechanism. Proc. Natl Acad Sci USA 2002 99 12606 12611.
63. Okabe J, Eguchi A, Masago A, Hayakawa T, Nakanishi M. TRF1 is a critical trans-acting factor required for de novo telomere formation in human cells. Hum. Mol. Genet. 2000 9 2639 2650.
64. Muntoni A, Reddel RR. The first molecular details of ALT in human tumor cells. Hum. Mol. Genet. 2005 2 R191 R196.
65. Rouse J, Jackson SP. Interfaces between the detection, signaling, and repair of DNA damage. Science 2002 297 547 551.
66. Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 2000 408 433 439.
67. Blanes A, Diaz-Cano SJ. Complementary analysis of microsatellite tumor profile and mismatch repair defects in colorectal carcinomas. World J. Gastroenterol. 2006 12 5932 5940.
68. Cortez D, Guntuku S, Qin J, Elledge SJ. ATR and ATRIP: partners in checkpoint signaling. Science 2001 294 1713 1716.
69. Taniguchi T, Garcia-Higuera I, Xu B et al. Convergence of the fanconi anemia and ataxia telangiectasia signaling pathways. Cell 2002 109 459 472.
70. Venkitaraman AR. Cancer susceptibility and the functions of BRCA1 and BRCA2. Cell 2002 108 171 182.
71. Gibbons RJ. Histone modifying and chromatin remodelling enzymes in cancer and dysplastic syndromes. Hum. Mol. Genet. 2005 14 Spec No 1 R85 R92.
72. Murnion ME, Adams RR, Callister DM, Allis CD, Earnshaw WC, Swedlow JR. Chromatin-associated protein phosphatase 1 regulates aurora-B and histone H3 phosphorylation. J. Biol. Chem. 2001 276 26656 26665.
73. Ball AR Jr., Schmiesing JA, Zhou C et al. Identification of a chromosome-targeting domain in the human condensin subunit CNAP1/hCAP-D2/Eg7. Mol. Cell. Biol. 2002 22 5769 5781.
74. Akileswaran L, Taraska JW, Sayer JA, Gettemy JM, Coghlan VM. A-kinase-anchoring protein AKAP95 is targeted to the nuclear matrix and associates with p68 RNA helicase. J. Biol. Chem. 2001 276 17448 17454.
75. Plass C. Cancer epigenomics. Hum. Mol. Genet. 2002 11 2479 2488.
76. Dilworth FJ, Chambon P. Nuclear receptors coordinate the activities of chromatin remodeling complexes and coactivators to facilitate initiation of transcription. Oncogene 2001 20 3047 3054.
77. Feng Q, Zhang Y. The MeCP1 complex represses transcription through preferential binding, remodeling, and deacetylating methylated nucleosomes. Genes Dev. 2001 15 827 832.
78. Nan X, Ng HH, Johnson CA et al. Transcriptional repression by the methyl-CpG-binding protein MeCP2 involves a histone deacetylase complex. Nature 1998 393 386 389.
79. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell 2000 103 253 262.
80. Proud CG. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. Biochem. J. 2007 403 217 234.
81. Shaw RJ, Cantley LC. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006 441 424 430.
82. West MJ, Stoneley M, Willis AE. Translational induction of the c-myc oncogene via activation of the FRAP/TOR signalling pathway. Oncogene 1998 17 769 780.
83. Broker LE, Kruyt FA, Giaccone G. Cell death independent of caspases: a review. Clin. Cancer Res. 2005 11 3155 3162.
84. Henry-Mowatt J, Dive C, Martinou JC, James D. Role of mitochondrial membrane permeabilization in apoptosis and cancer. Oncogene 2004 23 2850 2860.
85. Modica-Napolitano JS, Kulawiec M, Singh KK. Mitochondria and human cancer. Curr. Mol. Med. 2007 7 121 131.
86. Singh KK. Mitochondrial dysfunction is a common phenotype in aging and cancer. Ann. NY Acad. Sci. 2004 1019 260 264.
87. Wallace DC. A mitochondrial paradigm of metabolic and degenerative diseases, aging, and cancer: a dawn for evolutionary medicine. Annu. Rev. Genet. 2005 39 359 407.
88. Irminger-Finger I. Science of cancer and aging. J. Clin. Oncol. 2007 25 1844 1851.
89. Neuzil J, Stantic M, Zobalova R et al. Tumour-initiating cells vs. cancer 'stem' cells and CD133: What's in the name? Biochem. Biophys. Res. Commun. 2007 355 855 859.
90. Maximo V, Botelho T, Capela J et al. Somatic and germline mutation in GRIM-19, a dual function gene involved in mitochondrial metabolism and cell death, is linked to mitochondrion-rich (Hurthle cell) tumours of the thyroid. Br. J. Cancer 2005 92 1892 1898.
91. Maximo V, Soares P, Lima J, Cameselle-Teijeiro J, Sobrinho-Simoes M. Mitochondrial DNA somatic mutations (point mutations and large deletions) and mitochondrial DNA variants in human thyroid pathology: a study with emphasis on Hurthle cell tumors. Am. J. Pathol. 2002 160 1857 1865.
92. Sobrinho-Simoes M, Maximo V, Castro IV et al. Hurthle (oncocytic) cell tumors of thyroid: etiopathogenesis, diagnosis and clinical significance. Int. J. Surg. Pathol. 2005 13 29 35.
93. Arias AM. Epithelial mesenchymal interactions in cancer and development. Cell 2001 105 425 431.
94. Gumbiner BM. Cell adhesion: the molecular basis of tissue architecture and morphogenesis. Cell 1996 84 345 357.
95. Muthuswamy SK. ErbB2 makes beta 4 integrin an accomplice in tumorigenesis. Cell 2006 126 443 445.
96. Burridge K, Wennerberg K. Rho and Rac take center stage. Cell 2004 116 167 179.
97. Blobel CP. Metalloprotease-disintegrins: links to cell adhesion and cleavage of TNF alpha and Notch. Cell 1997 90 589 592.
98. Montell DJ. Anchors away! Fos fosters anchor-cell invasion. Cell 2005 121 816 817.
99. Oh J, Takahashi R, Kondo S et al. The membrane-anchored MMP inhibitor RECK is a key regulator of extracellular matrix integrity and angiogenesis. Cell 2001 107 789 800.
100. Takahashi C, Sheng Z, Horan TP et al. Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl Acad Sci USA 1998 95 13221 13226.